Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 11/20 | 0.45 |
| ▸ | PLA2G7 | Q13093 | 2/20 | 0.42 |
| ▸ | ESRRA | P11474 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | CSF1R | P07333 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21264375 | 0.93 | PLA2G7 (0.42) | SLC22A12PLA2G7ESRRAARCSF1R | |
| SCHEMBL21264376 | 0.91 | SLC22A12 (0.40) | SLC22A12PLA2G7ESRRAARCSF1R | |
| SCHEMBL17884243 | 0.89 | PLA2G7 (0.50) | SLC22A12PLA2G7ESRRAAR | |
| SCHEMBL29642290 | 0.89 | PLA2G7 (0.50) | SLC22A12PLA2G7ESRRAAR | |
| SCHEMBL29642235 | 0.86 | PLA2G7 (0.52) | SLC22A12PLA2G7ESRRAAR | |
| SCHEMBL17884237 | 0.86 | PLA2G7 (0.52) | SLC22A12PLA2G7ESRRAAR | |
| SCHEMBL29642185 | 0.84 | AR (0.50) | SLC22A12PLA2G7ESRRAAR | |
| SCHEMBL17884213 | 0.84 | AR (0.50) | SLC22A12PLA2G7ESRRAAR | |
| SCHEMBL17884217 | 0.83 | PLA2G7 (0.60) | PLA2G7AR | |
| SCHEMBL20975880 | 0.82 | PLA2G7 (0.51) | SLC22A12PLA2G7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10787422-B2 | Pyrimidone compounds used as Lp-PLA2 inhibitors and pharmaceutical compositions thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2020-09-29 | — | — | US | disclosed |
| US-20190248751-A1 | Pyrimidone Compounds Used as Lp-PLA2 Inhibitors and Pharmaceutical Compositions Thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2019-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10787422-B2 | Pyrimidone compounds used as Lp-PLA2 inhibitors and pharmaceutical compositions thereof | PLA2G12B, PLA2G1B, PLA2G4A | SLC22A12 3009/4885PLA2G7 9/4885ESRRA 4239/4885 |
| US-20190248751-A1 | Pyrimidone Compounds Used as Lp-PLA2 Inhibitors and Pharmaceutical Compositions Thereof | PLA2G12B, PLA2G1B, PLA2G4A | SLC22A12 3009/4885PLA2G7 9/4885ESRRA 4239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.